Mainz Biomed (QUCY) Stock Price, News & Analysis

Company Overview

Mainz Biomed N.V. (NASDAQ: QUCY) is a molecular diagnostics company focused on developing and commercializing noninvasive screening solutions for cancer and other diseases. The company was founded in 2016 and is headquartered in Mainz, Germany.

Its principal product is ColoAlert, a stool-based molecular diagnostic test designed to screen for colorectal cancer by analyzing stool samples for genetic biomarkers associated with the disease. The test is intended to provide a convenient, noninvasive alternative to certain conventional screening methods and has been marketed in Germany and other European markets. Mainz Biomed has also pursued regulatory and clinical development activities for the product in the United States.

Mainz Biomed’s operations center on the research, development, regulatory advancement, and commercialization of molecular diagnostic products. The company’s leadership has included Guido Baechler as chief executive officer. Its geographic focus has included Europe and the United States, with expansion dependent on applicable regulatory approvals and market access.

Key Stats

• Today's Range: $0.90 to $1.23
• 50-Day Range: $1.03 to $1.60
• 52-Week Range: $0.30 to $4.93
• Volume: 1.98 million shs
• Average Volume: 413,545 shs
• Market Capitalization: $15.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 27% of companies evaluated by MarketBeat, and ranked 568th out of 659 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Hold

Consensus Rating

Mainz Biomed has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, no buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Mainz Biomed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mainz Biomed are expected to grow in the coming year, from ($0.49) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 14.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.35% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 5.45.

Change versus previous month

Short interest in Mainz Biomed has recently decreased by 13.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Mainz Biomed has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Industrials companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mainz Biomed this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for QUCY on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

3 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.10% of the stock of Mainz Biomed is held by insiders.

Percentage Held by Institutions

Mainz Biomed has minimal institutional ownership at this time.

Company Calendar

• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Aerospace & Defense
• Sub-Industry: Aerospace & Defense
• Current Symbol: NASDAQ:QUCY
• CIK: 1874252
• Web: quantum-cyber.ai
• Phone: 49 6131 5542860
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.56
• Quick Ratio: 5.56

Sales & Book Value

• Annual Sales: $537.08 thousand
• Price / Sales: 28.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 14.71

Miscellaneous

• Outstanding Shares: 14,661,000
• Free Float: 14,207,000
• Market Cap: $15.10 million
• Optionable: N/A
• Beta: 2.37